Pharma BD Deal Intelligence
Pfizer's acquisition of Emergen-C maker Alacer became a consumer-health orphan asset—a solid COVID-era performer whose strategic rationale evaporated when Pfizer exited consumer health into the 2019 GSK joint venture, now demerged as Haleon. The brand survives as a modest, low-growth line inside a much larger portfolio.
Pfizer, which had announced plans to divest nutrition and animal health, signaled it would retain and bulk up the consumer health unit by acquiring Alacer…
We expect that our global network and deep expertise in dietary supplements combined with our desire to provide consumers with high-quality products will make…
Pfizer acquires Emergen-C maker; companies said it will help expand Emergen-C distribution. Emergen-C products add to and greatly complement Pfizer's…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer Consumer Healthcare acquired Alacer Corp. (Emergen-C). Note: borderline consumer health rather than pharma; included for completeness given Pfizer's broader 2011 consumer-health roll-up.
Assessment window: 5yr post-close.
$221M US vitamin C category retail sales (year-to-Oct 2011) · $1.87B Pfizer nutrition division revenue at time of deal (separate from this acquisition)
Vitamin C / electrolyte effervescent powders are over-the-counter dietary supplements marketed for immune support and hydration. They are not regulated as drugs and do not treat a defined disease; demand is consumer-driven and seasonal, peaking in cold-and-flu season.
Emergen-C competes in the US vitamin C / immune-support OTC category against Nature Made (Pharmavite), Airborne (Reckitt/Schiff), Ester-C (NBTY), Centrum (Pfizer/GSK Consumer Healthcare), and private-label store brands. At deal time the US vitamin C category generated ~$221M annually with 2.8% growth across conventional and natural channels. Emergen-C was already the largest single branded vitamin C line in the US at ~500M packets/year, giving Pfizer Consumer Healthcare an immediate share-leading SKU rather than incremental volume. Strategically, the Alacer buy was the bookend to Pfizer's December 2011 Ferrosan consumer-health acquisition and signaled that CEO Ian Read intended to retain and reinforce consumer healthcare even while divesting the separate nutrition (infant formula) and animal health units. The deal added a single-brand effervescent franchise that complemented multivitamins (Centrum) and supplements (Caltrate), strengthening Pfizer's mass-channel shelf presence ahead of the eventual GSK consumer-health JV (2019). Note: this is a borderline pharma transaction — strictly OTC/supplement, not Rx — and is included only because of Pfizer's broader 2011-2012 consumer-health roll-up.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Alacer Corp. (this deal) | 2011 | — | 61 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2011 deals · Pfizer Inc. deals · Other deals